HMGB-A box, a competitive antagonist of HMGB1, and glycyrrhizin, a small molecule inhibitor as well as RAGE antagonist peptide and ethyl pyruvate have been shown to block extracellular HMGB1 and affect cell proliferation and invasion in vitro, as well as leading to tumor growth suppression in vivo [38,39]. Here, HMGB1 is linked to neoplasm.